HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.
We have constructed, expressed, and purified a fusion protein, HAR-TX beta 2, consisting of heregulin-beta 2 fused to a binding-defective form of Pseudomonas exotoxin A, PE40. The fusion protein was found to induce receptor tyrosine phosphorylation in CEM cells transfected with HER4 alone or in combination with HER2 but not in cells transfected with HER2 or HER1 alone. The phosphorylation of receptor tyrosines was both dose-dependent and saturable in amounts similar to those shown to be active for native heregulin. HAR-TX beta 2 was specifically cytotoxic toward a variety of carcinoma cell lines in the ng/ml range. However, some tumor cell lines were found to be insensitive to the cytotoxic action of the fusion protein even at > 2 micrograms/ml. Relative amounts of HER4, HER3, and HER2 were determined on seven cell lines sensitive and four cell lines insensitive to HAR-TX beta 2. All lines that express HER4 were killed by HAR-TX beta 2, while none lacking HER4 were affected. HAR-TX beta 2 was able to bind to and signal via tyrosine phosphorylation in cell lines that co-express HER2 and HER3 in the absence of HER4 without inducing cytotoxicity. Thus HAR-TX beta 2 may prove to be a useful reagent for the targeting and elimination of HER4-positive tumor cells.
Siegall
C B
CB
Molecular Immunology Department, Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
Bacus
S S
SS
Cohen
B D
BD
Plowman
G D
GD
Mixan
B
B
Chace
D
D
Chin
D M
DM
Goetze
A
A
Green
J M
JM
Hellström
I
I
D036002:ADP Ribose Transferases; D000595:Amino Acid Sequence; D000818:Animals; D001427:Bacterial Toxins / Q000494:pharmacology; D001483:Base Sequence; D001943:Breast Neoplasms; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D017931:DNA Primers; D066246:ErbB Receptors / Q000096:biosynthesis*; D005098:Exotoxins / Q000096:biosynthesis / Q000302:isolation & purification / Q000494:pharmacology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D006023:Glycoproteins / Q000096:biosynthesis / Q000302:isolation & purification / Q000494:pharmacology*; D006801:Humans; D000922:Immunotoxins / Q000302:isolation & purification / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D015458:Leukemia, T-Cell; D008175:Lung Neoplasms; D008297:Male; D008969:Molecular Sequence Data; D020880:Neuregulins; D010051:Ovarian Neoplasms; D010766:Phosphorylation; D019000:Phosphotyrosine; D016133:Polymerase Chain Reaction; D011471:Prostatic Neoplasms; D011550:Pseudomonas aeruginosa; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D066247:Receptor, ErbB-4; D011993:Recombinant Fusion Proteins; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D017931:DNA Primers; D066246:ErbB Receptors; D005098:Exotoxins; D006023:Glycoproteins; D000922:Immunotoxins; D020880:Neuregulins; D019000:Phosphotyrosine; D012333:RNA, Messenger; D066247:Receptor, ErbB-4; D011993:Recombinant Fusion Proteins; D014443:Tyrosine; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C101006:HAR-TX beta 2 protein, recombinant; C587689:ERBB4 protein, human; C587691:Erbb4 protein, rat